{
  "pmcid": "1876947",
  "sha256": "26932543dc1200658c28be33ddd144063ad79ab900cac8371e7afe15c4e705b9",
  "timestamp_utc": "2025-11-09T22:32:22.375345+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.464002100840336,
    "reading_ease": 29.17070378151263,
    "word_count": 224
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Adjuvant Interferon Therapy in Hepatitis B-Related Hepatocellular Carcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomly assigned to no treatment (control) or interferon alpha-2b 10 MIU/m² thrice weekly for 16 weeks (IFN-I group)"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with no residual disease after hepatic resection for HCC, predominantly hepatitis B-related, from February 1999 to June 2002"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to no treatment (control) or interferon alpha-2b 10 MIU/m² thrice weekly for 16 weeks (IFN-I group)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was overall survival, measured at 1 and 5 years"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence with allocation concealment"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Eighty patients were randomised: 40 to the control group and 40 to the IFN-I group"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Eighty patients were randomised: 40 to the control group and 40 to the IFN-I group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The relative risk of death for interferon treatment was 0.42 (95% CI, 0.17–1.05; P = 0.063)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse effects led to treatment discontinuation in the higher dose group"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}